4d pharma (LSE:DDDD) EPS (Basic) : £-0.32 (TTM As of Dec. 2021)

View and export this data going back to 2014. Start your Free Trial

What is 4d pharma EPS (Basic)?

4d pharma's basic earnings per share (Basic EPS) for the six months ended in Dec. 2021 was £-0.20. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2021 was £-0.32.

4d pharma's EPS (Diluted) for the six months ended in Dec. 2021 was £-0.20. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2021 was £-0.32.

4d pharma's EPS without NRI for the six months ended in Dec. 2021 was £-0.20. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2021 was -0.32.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

4d pharma EPS (Basic) Historical Data

The historical data trend for 4d pharma's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4d pharma EPS (Basic) Chart

4d pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

EPS (Basic)

Get a 7-Day Free Trial

-0.31

-0.39

-0.35

-0.23

-0.32

4d pharma Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21
EPS (Basic)	Get a 7-Day Free Trial											-0.17	-0.14	-0.09	-0.12	-0.20

4d pharma EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

4d pharma's Basic EPS for the fiscal year that ended in Dec. 2021 is calculated as

Basic EPS (A: Dec. 2021 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-53.96	-	0)	/	169.520
	=	-0.32

4d pharma's Basic EPS for the quarter that ended in Dec. 2021 is calculated as

Basic EPS (Q: Dec. 2021 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-35.948	-	0)	/	180.474
	=	-0.20

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2021 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.32

4d pharma (LSE:DDDD) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

4d pharma EPS (Basic) Related Terms

Thank you for viewing the detailed overview of 4d pharma's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

4d pharma (LSE:DDDD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4d pharma PLC (LSE:DDDD) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

9 Bond Court, Fifth Floor, Leeds, GBR, LS1 2JZ

Website

https://www.4dpharmaplc.com

4d pharma PLC and its subsidiaries are in the business of research and development and production of live biotherapeutic products. The company develops biotherapeutic products for diseases such as cancer, asthma, autism, and autoimmune conditions such as arthritis and multiple sclerosis. Its developing science includes Live biotherapeutics, Microbiome, MicroRx, MicroDx, and others.

4d pharma (LSE:DDDD) Headlines

No Headlines